Validation of the International Tumor Budding Consensus Conference 2016 recommendations on tumor budding in stage I-IV colorectal cancer.

[1]  Phil Quirke,et al.  Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016 , 2017, Modern Pathology.

[2]  D. Lambrechts,et al.  Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching , 2016, British Journal of Cancer.

[3]  A. Rogers,et al.  Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer , 2016, British Journal of Cancer.

[4]  G. Dorta,et al.  Nachsorge nach koloskopischer Polypektomie und entferntem Kolorektalkarzinom , 2016 .

[5]  M. Pollheimer,et al.  Tumour budding with and without admixed inflammation: two different sides of the same coin? , 2016, British Journal of Cancer.

[6]  J. Cerhan,et al.  Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort , 2015, The American journal of surgical pathology.

[7]  Heather Dawson,et al.  Tumour border configuration in colorectal cancer: proposal for an alternative scoring system based on the percentage of infiltrating margin , 2015, Histopathology.

[8]  Tetsuo Nemoto,et al.  A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study , 2015, Modern Pathology.

[9]  S. Barni,et al.  Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis , 2015, Journal of Gastrointestinal Cancer.

[10]  A. Lugli,et al.  Molecular and Pathogenetic Aspects of Tumor Budding in Colorectal Cancer , 2015, Front. Med..

[11]  D. McMillan,et al.  The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review. , 2015, Cancer treatment reviews.

[12]  Kenichi Sugihara,et al.  Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a multi-institution pathology review , 2014, Journal of Gastroenterology.

[13]  I. Zlobec,et al.  Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch Repair-Deficiency in Colorectal Cancer , 2013, Front. Oncol..

[14]  I. Nagtegaal,et al.  Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions , 2013, Endoscopy.

[15]  A. Radcliffe,et al.  Systematic review and meta‐analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[16]  R. Riddell,et al.  Tumor budding in colorectal carcinoma: time to take notice , 2012, Modern Pathology.

[17]  M. Pollheimer,et al.  Tumor Budding is an Independent Predictor of Outcome in AJCC/UICC Stage II Colorectal Cancer , 2012, Annals of Surgical Oncology.

[18]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer , 2011, International Journal of Clinical Oncology.

[19]  Henry Z. Montes,et al.  TNM Classification of Malignant Tumors, 7th edition , 2010 .

[20]  Wendy Frankel,et al.  Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. , 2009, Archives of pathology & laboratory medicine.

[21]  J. O’Sullivan,et al.  Tumor Budding is a Strong and Reproducible Prognostic Marker in T3N0 Colorectal Cancer , 2009, The American journal of surgical pathology.

[22]  H. Mitomi,et al.  Tumor Budding as an Index to Identify High-Risk Patients with Stage II Colon Cancer , 2008, Diseases of the colon and rectum.

[23]  J. Melkko,et al.  Inflammation and prognosis in colorectal cancer. , 2005, European journal of cancer.

[24]  Hidetaka Mochizuki,et al.  Risk factors for an adverse outcome in early invasive colorectal carcinoma. , 2004, Gastroenterology.

[25]  Tetsuro Nakamura,et al.  Budding Is Useful to Select High-Risk Patients in Stage II Well-Differentiated or Moderately Differentiated Colon Adenocarcinoma , 2003, Diseases of the colon and rectum.

[26]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .